Yes, IM Invanz (ertapenem) and oral linezolid can be safely administered together
There are no documented contraindications or clinically significant drug interactions between ertapenem and linezolid, and these agents can be used concurrently. The FDA label for Invanz does not list linezolid as a contraindicated or interacting medication 1.
Key Safety Considerations
No Direct Drug-Drug Interactions
- Neither the FDA prescribing information for ertapenem nor available clinical evidence identifies any pharmacokinetic or pharmacodynamic interactions between these two antibiotics
- The only documented drug interactions for ertapenem are with probenecid (which inhibits renal excretion) and valproic acid/divalproex sodium (carbapenems reduce valproic acid levels, increasing seizure risk) 1
- Linezolid is not mentioned in any interaction warnings
Complementary Antimicrobial Coverage
Research actually demonstrates these agents work well together:
- In vitro studies show synergistic or additive activity when linezolid and ertapenem are combined against resistant gram-positive organisms including MRSA and vancomycin-resistant enterococci 2, 3
- A rabbit endocarditis model confirmed highly synergistic activity in vivo against MRSA after 4 days of combination treatment 3
- Both antibiotics achieve adequate pleural fluid penetration with similar pharmacokinetic profiles when used together 4
Individual Monitoring Requirements
For ertapenem (Invanz):
- Monitor for seizure risk, especially in patients with CNS disorders or renal impairment 1
- Avoid in patients on valproic acid/divalproex (consider alternative antibiotics) 1
- Adjust dosing if creatinine clearance ≤30 mL/min/1.73 m² 1
- Watch for hypersensitivity reactions (beta-lactam allergy history) 1
For linezolid:
- Monitor complete blood counts for myelosuppression with prolonged use
- Watch for peripheral and optic neuropathy
- Monitor for serotonin syndrome if patient is on serotonergic agents
- No renal dose adjustment needed 5
Clinical Context Matters
This combination is particularly rational when treating:
- Polymicrobial infections requiring both gram-negative (including ESBL-producing organisms) and resistant gram-positive coverage
- Complicated intra-abdominal infections where enterococcal coverage is debated 6
- Skin and soft tissue infections with mixed flora 7
Important Caveats
- Ensure appropriate indication for both antibiotics - avoid unnecessary broad-spectrum coverage that promotes resistance 1
- Duration considerations: IM ertapenem is approved for up to 7 days; IV formulation can be used up to 14 days 1
- Avoid inadvertent intravascular injection when giving ertapenem IM 1
- Both agents can cause Clostridioides difficile-associated diarrhea - monitor for this complication 1